fig5

From: ImmuneScore as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with immune checkpoint inhibitor therapy

ImmuneScore as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with immune checkpoint inhibitor therapy

Figure 5. ImmuneScore as a prognostic indicator of OS in patients with non-squamous NSCLC receiving ICI therapy combined with chemotherapy. (A) ImmuneScore could predict median OS, with higher AUC than that of PD-L1 TPS; (B) Patients with high ImmuneScore had longer OS; (C) Higher ImmuneScore indicated longer OS in PD-L1 TPS ≥ 1% and PD-L1 TPS < 1% subgroups; (D) Higher ImmuneScore indicated longer OS in PD-L1 TPS ≥ 50% and PD-L1 TPS < 50% subgroups. NSCLC: Non-small cell lung cancer; ICI: immune checkpoint inhibitor; OS: overall survival; PD-L1 TPS: programmed cell death 1 ligand 1 tumor proportion score; AUC: area under the ROC curve; IS: ImmuneScore; HR: hazard ratio.

fig5

Portico

Portico